Pradžia › Ūmi bifeninė leukemija › Wisconsin
Ūmi bifeninė leukemija klinikiniai tyrimai Wisconsin
5 tyrimai dėl Ūmi bifeninė leukemija ieško dalyvių vietose Wisconsin.
Miestai Wisconsin
Oficialus tyrimo tekstas (anglų kalba)
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- Children's Hospital of Wisconsin, Milwaukee
Renkami dalyviai2 fazė
365 Days · Visoms lytims · Atnaujinta 2026-09-25 · NCT06317662Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
- Marshfield Medical Center-Marshfield, Marshfield
- ir dar 1
Renkami dalyviai3 fazė
365 Days – 25 Years · Visoms lytims · Atnaujinta 2026-08-25 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
- Marshfield Medical Center-Marshfield, Marshfield
Renkami dalyviai1/2 fazė
Iki 22 metų · Visoms lytims · Atnaujinta 2026-08-25 · NCT04726241MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
- Children's Wisconsin, Milwaukee
Renkami dalyviai
Amžius nuo 0 iki 25 · Visoms lytims · Atnaujinta 2026-05-13 · NCT05794880Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Children's Hospital of Wisconsin, Milwaukee
Renkami dalyviai1 fazė
Amžius nuo 1 iki 21 · Visoms lytims · Atnaujinta 2024-12-06 · NCT05476770Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.